The CONSORT-EHEALTH checklist is intended for authors of randomized trials evaluating webbased and Internet-based applications/interventions, including mobile interventions, electronic games (incl multiplayer games), social media, certain telehealth applications, and other interactive and/or networked electronic applications. Some of the items (e.g. all subitems under item 5 description of the intervention) may also be applicable for other study designs.

The goal of the CONSORT EHEALTH checklist and guideline is to be a) a guide for reporting for authors of RCTs, b) to form a basis for appraisal of an ehealth trial (in terms of validity)

CONSORT-EHEALTH items/subitems are MANDATORY reporting items for studies published in the Journal of Medical Internet Research and other journals / scientific societies endorsing the checklist.

Items numbered 1., 2., 3., 4a., 4b etc are original CONSORT or CONSORT-NPT (non-pharmacologic treatment) items.

Items with Roman numerals (i., ii, iii, iv etc.) are CONSORT-EHEALTH extensions/clarifications.

As the CONSORT-EHEALTH checklist is still considered in a formative stage, we would ask that you also RATE ON A SCALE OF 1-5 how important/useful you feel each item is FOR THE PURPOSE OF THE CHECKLIST and reporting guideline (optional).

Mandatory reporting items are marked with a red \*.

In the textboxes, either copy & paste the relevant sections from your manuscript into this form please include any quotes from your manuscript in QUOTATION MARKS, or answer directly by providing additional information not in the manuscript, or elaborating on why the item was not relevant for this study.

YOUR ANSWERS WILL BE PUBLISHED AS A SUPPLEMENTARY FILE TO YOUR PUBLICATION IN JMIR AND ARE CONSIDERED PART OF YOUR PUBLICATION (IF ACCEPTED). Please fill in these questions diligently. Information will not be copyedited, so please use proper spelling and grammar, use correct capitalization, and avoid abbreviations.

DO NOT FORGET TO SAVE AS PDF \_AND\_ CLICK THE SUBMIT BUTTON SO YOUR ANSWERS ARE IN OUR DATABASE !!!

Citation Suggestion (if you append the pdf as Appendix we suggest to cite this paper in the caption):

Eysenbach G, CONSORT-EHEALTH Group CONSORT-EHEALTH: Improving and Standardizing Evaluation Reports of Web-based and Mobile Health Interventions J Med Internet Res 2011;13(4):e126 URL: http://www.jmir.org/2011/4/e126/ doi: 10.2196/jmir.1923 PMID: 22209829

\*Required

Your name *	
First Last	
Li-Ang Lee	

University of Toronto, Toronto, Canada

Chang Gung University, Taoy

Your e-mail address \*

<u>abc@gmail.com</u>

5738@cgmh.org.tw

Title of your manuscript \*

Provide the (draft) title of your manuscript.

Cognitive Style and Mobile E-Learning in Emergent Otorhinolaryngology-Head and Neck Surgery Disorders for Millennial Undergraduate Medical Students: A Randomized Controlled Trial

#### Article Preparation Status/Stage \*

At which stage in your article preparation are you currently (at the time you fill in this form)

- not submitted yet in early draft status
- not submitted yet in late draft status, just before submission
- submitted to a journal but not reviewed yet
- submitted to a journal and after receiving initial reviewer comments
- submitted to a journal and accepted, but not published yet
- o published
- Other:

#### Journal \*

If you already know where you will submit this paper (or if it is already submitted), please provide the journal name (if it is not JMIR, provide the journal name under "other")

- not submitted yet / unclear where I will submit this
- Journal of Medical Internet Research (JMIR)
- Other:

#### Manuscript tracking number \*

If this is a JMIR submission, please provide the manuscript tracking number under "other" (The ms tracking number can be found in the submission acknowledgement email, or when you login as author in JMIR. If the paper is already published in JMIR, then the ms tracking number is the four-digit number at the end of the DOI, to be found at the bottom of each published article in JMIR)

no ms number (yet) / not (yet) submitted to / published in JMIR

### TITLE AND ABSTRACT

## 1a) TITLE: Identification as a randomized trial in the title

1a) Does your paper address CONSORT item 1a? \*

#### 2017/11/9

#### CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form

I.e does the title contain the phrase "Randomized Controlled Trial"? (if not, explain the reason under "other")

- yes
- Other:

#### 1a-i) Identify the mode of delivery in the title

Identify the mode of delivery. Preferably use "web-based" and/or "mobile" and/or "electronic game" in the title. Avoid ambiguous terms like "online", "virtual", "interactive". Use "Internet-based" only if Intervention includes non-web-based Internet components (e.g. email), use "computer-based" or "electronic" only if offline products are used. Use "virtual" only in the context of "virtual reality" (3-D worlds). Use "online" only in the context of "online support groups". Complement or substitute product names with broader terms for the class of products (such as "mobile" or "smart phone" instead of "iphone"), especially if the application runs on different platforms.

1 2 3 4 5 subitem not at all important O O O O essential

#### Does your paper address subitem 1a-i? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Mobile E-Learning		
		1

#### 1a-ii) Non-web-based components or important co-interventions in title

Mention non-web-based components or important co-interventions in title, if any (e.g., "with telephone support").

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$		$\bigcirc$	$\bigcirc$	essential

#### Does your paper address subitem 1a-ii?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

#### 1a-iii) Primary condition or target group in the title

Mention primary condition or target group in the title, if any (e.g., "for children with Type I Diabetes") Example: A Web-based and Mobile Intervention with Telephone Support for Children with Type I Diabetes: Randomized Controlled Trial

1 2 3 4 5

subitem not at all important 🔘 🔘 💿 essential

#### Does your paper address subitem 1a-iii? \*

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

for Millennial Undergraduate Medical Students

# 1b) ABSTRACT: Structured summary of trial design, methods, results, and conclusions

NPT extension: Description of experimental treatment, comparator, care providers, centers, and blinding status.

## 1b-i) Key features/functionalities/components of the intervention and comparator in the METHODS section of the ABSTRACT

Mention key features/functionalities/components of the intervention and comparator in the abstract. If possible, also mention theories and principles used for designing the site. Keep in mind the needs of systematic reviewers and indexers by including important synonyms. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	essential

#### Does your paper address subitem 1b-i? \*

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

They were randomly assigned (1:1) to a novel interactive multimedia (IM) group and conventional PowerPoint show (PPS) group matched by age, sex, and cognitive style. The content for the gamified IM module was derived from and corresponded to the textbook-based learning material of the PPS module (video lectures).

#### 1b-ii) Level of human involvement in the METHODS section of the ABSTRACT

Clarify the level of human involvement in the abstract, e.g., use phrases like "fully automated" vs. "therapist/nurse/care provider/physician-assisted" (mention number and expertise of providers involved, if any). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	$\bigcirc$	essential

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The participants were unblinded and used fully automated coursewa containing the IM or PPS module on a 7-inch tablet for 100 minutes.	re
	11

# 1b-iii) Open vs. closed, web-based (self-assessment) vs. face-to-face assessments in the METHODS section of the ABSTRACT

Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic or a closed online user group (closed usergroup trial), and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment). Clearly say if outcomes were self-assessed through questionnaires (as common in web-based trials). Note: In traditional offline trials, an open trial (open-label trial) is a type of clinical trial in which both the researchers and participants know which treatment is being administered. To avoid confusion, use "blinded" or "unblinded" to indicated the level of blinding instead of "open", as "open" in web-based trials usually refers to "open access" (i.e. participants can self-enrol). (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

			-	-	-	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$oldsymbol{O}$	$\bigcirc$	essential

#### Does your paper address subitem 1b-iii?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Knowledge and competence were assessed using multiple choice questions and multimedia situation tests, respectively. Each participant also rated their global satisfaction and learning experience using an AttrakDiff2 questionnaire.

1 2 3 4 5

#### 1b-iv) RESULTS section in abstract must contain use data

Report number of participants enrolled/assessed in each group, the use/uptake of the intervention (e.g., attrition/adherence metrics, use over time, number of logins etc.), in addition to primary/secondary outcomes. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$		essential

#### Does your paper address subitem 1b-iv?

All of the participants (median age 23 years, range 22–26 years; 36 males and 24 females) received the intended intervention after randomization. Overall, the participants had significant gains in knowledge (median 50%, interquartile range [IQR] 17–80%, P<.001) and competence (median 13%, IQR 0–33%, P=.006). There were no significant differences in knowledge gain (40% [IQR 13–76%] vs 60% [IQR 20–100%], P=.42) and competence gain (0% [IQR -21–38%] vs 25% [IQR 0–33%], P=.16) between the IM and PPS groups. However,

#### 1b-v) CONCLUSIONS/DISCUSSION in abstract for negative trials

Conclusions/Discussions in abstract for negative trials: Discuss the primary outcome - if the trial is negative (primary outcome not changed), and the intervention was not used, discuss whether negative results are attributable to lack of uptake and discuss reasons. (Note: Only report in the abstract what the main paper is reporting. If this information is missing from the main body of text, consider adding it)

1 2 3 4 5 subitem not at all important O O O O essential

#### Does your paper address subitem 1b-v?

Copy and paste relevant sections from the manuscript abstract (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Mobile e-learning is an effective modality to improve knowledge of emergent ORL-HNS in millennial undergraduate medical students. Our findings suggest the necessity of developing various modules for undergraduate medical students with different cognitive styles.

### INTRODUCTION

# 2a) In INTRODUCTION: Scientific background and explanation of rationale

#### 2a-i) Problem and the type of system/solution

Describe the problem and the type of system/solution that is object of the study: intended as stand-alone intervention vs. incorporated in broader health care program? Intended for a particular patient population? Goals of the intervention, e.g., being more cost-effective to other interventions, replace or complement other solutions? (Note: Details about the intervention are provided in "Methods" under 5)

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 2a-i? \*

The large investment involved in undergraduate medical education (UME) for students and society has led medical schools worldwide to seek strategies and methods to improve their students' progress [1-3]. The cost of medical school tuition continues to increase annually [4], and medical students face substantial financial stress in the USA and Taiwan [5]. A reduction in medical training time has been shown to reduce medical school tuition fees [6]. Innovative curricula, quality of teaching, and primary care education are three major issues in UME

#### 2a-ii) Scientific background, rationale: What is known about the (type of) system

Scientific background, rationale: What is known about the (type of) system that is the object of the study (be sure to discuss the use of similar systems for other conditions/diagnoses, if appropiate), motivation for the study, i.e. what are the reasons for and what is the context for this specific study, from which stakeholder viewpoint is the study performed, potential impact of findings [2]. Briefly justify the choice of the comparator.

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 2a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Mobile technology has gained popularity in recent years as a means of immediate interactive multimedia (IM) communication and to access the Internet. Embedded e-learning in a smartphone or tablet can affect the educational environment. In this context, it has been termed "mobile technology in e-learning (M-TEL)", and it has been reported to represent the next natural frontier in the evolution of e-learning [19]. Almost all e-learning today can be assessed from mobile-devices including medical education [20], patient education [21], and the development of mobile

## 2b) In INTRODUCTION: Specific objectives or hypotheses

#### Does your paper address CONSORT subitem 2b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the current study, we hypothesized that FI learners would prefer M-TEL technology compared to FD learners, and that they would have a better performance with a novel IM module (cases) compared with a conventional PowerPoint show (PPS) module (controls). The control group also received identical instructional materials using the same mobile device.

### METHODS

# 3a) Description of trial design (such as parallel, factorial) including allocation ratio

#### Does your paper address CONSORT subitem 3a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information

not in the ms, or briefly explain why the item is not applicable/relevant for your study

We conducted this prospective study from August 1, 2015 to July 31, 2017 at a university (Department of ORL-HNS, Faculty of Medicine, Chang Gung University, Taoyuan, Taiwan). This study included two parts: 1) pilot system-design study, and 2) validation study. This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (No: 105-5290C), and all procedures were conducted in compliance with the Helsinki Declaration of 1975. The participants were informed about the aims of the study and written informed consent was

# 3b) Important changes to methods after trial commencement (such as eligibility criteria), with reasons

#### Does your paper address CONSORT subitem 3b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, this study have no important changes to methods after trial commencement.

#### 3b-i) Bug fixes, Downtimes, Content Changes

Bug fixes, Downtimes, Content Changes: ehealth systems are often dynamic systems. A description of changes to methods therefore also includes important changes made on the intervention or comparator during the trial (e.g., major bug fixes or changes in the functionality or content) (5-iii) and other "unexpected events" that may have influenced study design such as staff changes, system failures/downtimes, etc. [2].

subitem not at all important 🔘 🔘 💿 💿 essential

1

2 3

4 5


#### Does your paper address subitem 3b-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Major bug fixes were performed before the validation study.

### 4a) Eligibility criteria for participants

#### Does your paper address CONSORT subitem 4a? \*



#### 4a-i) Computer / Internet literacy

Computer / Internet literacy is often an implicit "de facto" eligibility criterion - this should be explicitly clarified.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	essential

#### Does your paper address subitem 4a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All of the volunteers had at least a basic level of computer literacy, and they were shown the practical aspects of using tablets and applications.

#### 4a-ii) Open vs. closed, web-based vs. face-to-face assessments:

Open vs. closed, web-based vs. face-to-face assessments: Mention how participants were recruited (online vs. offline), e.g., from an open access website or from a clinic, and clarify if this was a purely web-based trial, or there were face-to-face components (as part of the intervention or for assessment), i.e., to what degree got the study team to know the participant. In online-only trials, clarify if participants were quasi-anonymous and whether having multiple identities was possible or whether technical or logistical measures (e.g., cookies, email confirmation, phone calls) were used to detect/prevent these.



#### Does your paper address subitem 4a-ii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A total of 60 consecutive volunteers were recruited from a teaching clinic in
the validation study between November 23, 2016 and July 5, 2017.
There were five different face-to-face assessments.

#### 4a-iii) Information giving during recruitment

Information given during recruitment. Specify how participants were briefed for recruitment and in the informed consent procedures (e.g., publish the informed consent documentation as appendix, see also

item X26), as this information may have an effect on user self-selection, user expectation and may also bias results.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	essential

#### Does your paper address subitem 4a-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The participants were informed about the aims of the study and written informed consent was obtained from all participants.

### 4b) Settings and locations where the data were collected

#### Does your paper address CONSORT subitem 4b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We conducted this prospective study from August 1, 2015 to July 31, 2017 at a university (Department of ORL-HNS, Faculty of Medicine, Chang Gung University, Taoyuan, Taiwan).

#### 4b-i) Report if outcomes were (self-)assessed through online questionnaires

Clearly report if outcomes were (self-)assessed through online questionnaires (as common in web-based trials) or otherwise.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$		$\bigcirc$	$\bigcirc$	essential

#### Does your paper address subitem 4b-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no self-assessed outcomes through online questionnaire in this study.	
	11

#### 4b-ii) Report how institutional affiliations are displayed

Report how institutional affiliations are displayed to potential participants [on ehealth media], as affiliations with prestigious hospitals or universities may affect volunteer rates, use, and reactions with regards to an intervention.(Not a required item – describe only if this may bias results)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	essential

#### Does your paper address subitem 4b-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The funding source had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and the decision to submit the manuscript for publication.

### 5) The interventions for each group with sufficient details to allow replication, including how and when they were actually administered

#### 5-i) Mention names, credential, affiliations of the developers, sponsors, and owners

Mention names, credential, affiliations of the developers, sponsors, and owners [6] (if authors/evaluators are owners or developer of the software, this needs to be declared in a "Conflict of interest" section or mentioned elsewhere in the manuscript).



#### Does your paper address subitem 5-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This work was financially supported by grants from the Ministry of Science and Technology, Taiwan, R.O.C. (104-2511-S-182-010 & 105-2511-S-
182A-006) and a grant from the Chang Gung Medical Foundation, Taiwan, R.O.C. (CMRPG3F1091).

#### 5-ii) Describe the history/development process

Describe the history/development process of the application and previous formative evaluations (e.g., focus groups, usability testing), as these will have an impact on adoption/use rates and help with interpreting results.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	essential

#### Does your paper address subitem 5-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In the pilot system-design study [26], we established the instructional materials including essential knowledge and competence of the 10 most common emergent ORL-HNS disorders using the analysis, design, development, implementation, and evaluation models [27] to design effective instruction for e-learning (Figure 1). All of the materials were developed according to the results of needs assessment in a focus group of undergraduate students, and revised using a two-round modified Delphi method to develop the instructional content and assess

#### 5-iii) Revisions and updating

Revisions and updating. Clearly mention the date and/or version number of the application/intervention (and comparator, if applicable) evaluated, or describe whether the intervention underwent major changes during the evaluation process, or whether the development and/or content was "frozen" during the trial. Describe dynamic components such as news feeds or changing content which may have an impact on the replicability of the intervention (for unexpected events see item 3b).

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$		$\bigcirc$	essential

#### Does your paper address subitem 5-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Major b	bug fixes were performed before the validation study.	
		11

#### 5-iv) Quality assurance methods

Provide information on quality assurance methods to ensure accuracy and quality of information provided [1], if applicable.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	essential

#### Does your paper address subitem 5-iv?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The instructional content of the two learning modules was confirmed to be correlated and equivalent by two investigators from the study team (r=0.91, P<.001, Spearman correlation test) using the Software Evaluation Checklist [28]. This checklist uses seven criteria (curriculum connections, age/grade appreciates, investment justification, lay-out, support materials, instructional content, graphics/multimedia) with two (yes, no) Likert-type scales (a total of 28 questions).

#### 5-v) Ensure replicability by publishing the source code, and/or providing screenshots/screencapture video, and/or providing flowcharts of the algorithms used

Ensure replicability by publishing the source code, and/or providing screenshots/screen-capture video, and/or providing flowcharts of the algorithms used. Replicability (i.e., other researchers should in principle be able to replicate the study) is a hallmark of scientific reporting.

	1	2	3	4	5	
 		_	_	_	_	

subitem not at all important O O O O essential

#### Does your paper address subitem 5-v?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The Novel IM Module Using the IM module, the learners could operate a leading character to search for and interact with other non-player characters to procure instructional materials, to review acquired instructional slides (maximal 80), and to win five small game-based quizzes (Figure 3). The instructional slides were briefly explained using scrolling text. The content for the novel IM module was derived from and corresponded to the textbook-based learning material of the conventional PPS module. Game-based quizzes with different contexts

#### 5-vi) Digital preservation

Digital preservation: Provide the URL of the application, but as the intervention is likely to change or disappear over the course of the years; also make sure the intervention is archived (Internet Archive, <u>webcitation.org</u>, and/or publishing the source code or screenshots/videos alongside the article). As pages behind login screens cannot be archived, consider creating demo pages which are accessible without login.



#### Does your paper address subitem 5-vi?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, the application has not been released to date.	
	11

#### 5-vii) Access


Access: Describe how participants accessed the application, in what setting/context, if they had to pay (or were paid) or not, whether they had to be a member of specific group. If known, describe how participants obtained "access to the platform and Internet" [1]. To ensure access for editors/reviewers/readers, consider to provide a "backdoor" login account or demo mode for reviewers/readers to explore the application (also important for archiving purposes, see vi).

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 5-vii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



# 5-viii) Mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework

Describe mode of delivery, features/functionalities/components of the intervention and comparator, and the theoretical framework [6] used to design them (instructional strategy [1], behaviour change techniques, persuasive features, etc., see e.g., [7, 8] for terminology). This includes an in-depth description of the content (including where it is coming from and who developed it) [1]," whether [and how] it is tailored to individual circumstances and allows users to track their progress and receive feedback" [6]. This also includes a description of communication delivery channels and – if computer-mediated communication is a component – whether communication was synchronous or asynchronous [6]. It also includes information on presentation strategies [1], including page design principles, average amount of text on pages, presence of hyperlinks to other resources, etc. [1].

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 5-viii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Storyboards and courseware of the IM and PPS modules were developed using the same user interface (Figure 2). The Novel IM Module Using the IM module, the learners could operate a leading character to search for and interact with other non-player characters to procure instructional materials, to review acquired instructional slides (maximal 80), and to win five small game-based quizzes (Figure 3). The instructional slides were briefly explained using scrolling text. The content for the novel IM module was derived from and

#### 5-ix) Describe use parameters

Describe use parameters (e.g., intended "doses" and optimal timing for use). Clarify what instructions or recommendations were given to the user, e.g., regarding timing, frequency, heaviness of use, if any, or was the intervention used ad libitum.



#### Does your paper address subitem 5-ix?

After randomization, the participants were unblinded to use a fully automated courseware containing IM or PPS module on a 7-inch table	et in
an ordinary office environment for 100 minutes.	
	11

Clarify the level of human involvement (care providers or health professionals, also technical assistance) in the e-intervention or as co-intervention (detail number and expertise of professionals involved, if any, as well as "type of assistance offered, the timing and frequency of the support, how it is initiated, and the medium by which the assistance is delivered". It may be necessary to distinguish between the level of human involvement required for the trial, and the level of human involvement required for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$		$\bigcirc$	essential

#### Does your paper address subitem 5-x?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

a	er randomization, the participants were unblinded to use a fully tomated courseware containing IM or PPS module on a 7-inch tablet in ordinary office environment for 100 minutes.	
		//

#### 5-xi) Report any prompts/reminders used

Report any prompts/reminders used: Clarify if there were prompts (letters, emails, phone calls, SMS) to use the application, what triggered them, frequency etc. It may be necessary to distinguish between the level of prompts/reminders required for the trial, and the level of prompts/reminders for a routine application outside of a RCT setting (discuss under item 21 – generalizability).

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$		$\bigcirc$	essential

#### Does your paper address subitem 5-xi? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no prompts/reminders used.

Describe any co-interventions (incl. training/support): Clearly state any interventions that are provided in addition to the targeted eHealth intervention, as ehealth intervention may not be designed as stand-alone intervention. This includes training sessions and support [1]. It may be necessary to distinguish between the level of training required for the trial, and the level of training for a routine application outside of a RCT setting (discuss under item 21 – generalizability.

1 2 3 4 5

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 5-xii? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Before to use the courseware, the participants were explained the functionality of the tablet.

# 6a) Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed

#### Does your paper address CONSORT subitem 6a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The primary outcome measure was the percentage change in MCQ score (i.e. "knowledge gain") after the M-TEL. Other outcomes were the percentage changes in MST (i.e. "competence gain"), GSS, and AttrakDiff2 questionnaire scores.

6a-i) Online questionnaires: describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed

If outcomes were obtained through online questionnaires, describe if they were validated for online use and apply CHERRIES items to describe how the questionnaires were designed/deployed [9].

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 🔘 essential

**Does your paper address subitem 6a-i?** Copy and paste relevant sections from manuscript text

There were no online questionnaire in this study.         Ga-ii) Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 escribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored         0 pescribe whether, how, and when qualitative feedback from participants was obtained         0 pescribe whether, how, and when qualitative feedback from participants was obtained (e.g., through en feedback forms, interviews, focus groups).         1 2 3 4 5         subitem not at all important • • • • • • • • • • • • • • • • • • •		CONSORT-EHEALTH (V 1.6.1) - Submission/Publication Form	
defined/measured/monitored         Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.         1       2       3       4       5         subitem not at all important       Important       Important       Important       Important         Does your paper address subitem 6a-ii?       Copy and paste relevant sections from manuscript text         Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1).         6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through enfeedback forms, interviews, focus groups).         1       2       3       4       5         subitem not at all important       Important       Important       Important       Important         1       2       3       4       5         subitem not at all important       Important       Important       Important         1       2       3       4       5         subitem not at all important       Important       Important       Important         1       2       3       4       5 <th>There were</th> <th>o online questionnaire in this study.</th> <th></th>	There were	o online questionnaire in this study.	
defined/measured/monitored         Describe whether and how "use" (including intensity of use/dosage) was defined/measured/monitored (logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.         1       2       3       4       5         subitem not at all important       Important       Important       Important       Important         Does your paper address subitem 6a-ii?       Copy and paste relevant sections from manuscript text         Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1).			
(logins, logfile analysis, etc.). Use/adoption metrics are important process outcomes that should be reported in any ehealth trial.          1       2       3       4       5         subitem not at all important       Image:			
subitem not at all important	(logins, logfi	analysis, etc.). Use/adoption metrics are important process outcomes that should be	d
Does your paper address subitem 6a-ii?         Copy and paste relevant sections from manuscript text         Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1).		1 2 3 4 5	
Copy and paste relevant sections from manuscript text Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1).  6a-iii) Describe whether, how, and when qualitative feedback from participants was obtained Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through en feedback forms, interviews, focus groups).  1 2 3 4 5 subitem not at all important  Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text Qualitative feedback from participants was obtained through feedback	subitem not	all important 🔘 🔘 🔘 💿 essential	
Describe whether, how, and when qualitative feedback from participants was obtained (e.g., through en feedback forms, interviews, focus groups). 1 2 3 4 5 subitem not at all important • • • • • essential Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text Qualitative feedback from participants was obtained through feedback			
subitem not at all important	Describe wh	ner, how, and when qualitative feedback from participants was obtained (e.g., through e	mail
Does your paper address subitem 6a-iii? Copy and paste relevant sections from manuscript text Qualitative feedback from participants was obtained through feedback		1 2 3 4 5	
Copy and paste relevant sections from manuscript text Qualitative feedback from participants was obtained through feedback	subitem not	all important 🔘 🔘 🔘 💿 essential	
Qualitative feedback from participants was obtained through feedback			
	Qualitative	edback from participants was obtained through feedback	

# 6b) Any changes to trial outcomes after the trial commenced, with reasons

#### Does your paper address CONSORT subitem 6b? \*

No, we did not change trial outcomes after the trial commenced.

### 7a) How sample size was determined

NPT: When applicable, details of whether and how the clustering by care provides or centers was addressed

# 7a-i) Describe whether and how expected attrition was taken into account when calculating the sample size

Describe whether and how expected attrition was taken into account when calculating the sample size.



#### Does your paper address subitem 7a-i?

Copy and paste relevant sections from manuscript title (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

A priori sample size was estimated using primary outcome effects (percentage change in MCQ score) based on a pilot study (IM module:  $43\pm18\%$ ; PPS module:  $35\pm21\%$ ). A two-tailed Wilcoxon signed-rank test to calculate the sample size of 26 in each group (normal parent distribution; calculated effect size, 0.41; type I error, 0.05; power, 80%). Assuming a 10% drop-out rate to fulfill the criteria of intention-to-treat analysis, we needed at least 29 participants in each group. Accordingly, we decided to enroll a total of 60 students to show the difference in

# 7b) When applicable, explanation of any interim analyses and stopping guidelines

#### Does your paper address CONSORT subitem 7b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Nothing.

# 8a) Method used to generate the random allocation sequence

NPT: When applicable, how care providers were allocated to each trial group

#### Does your paper address CONSORT subitem 8a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Computer-generated lists of random numbers were created using the Random Number Generator in IBM SPSS software (version 23; IBM, Armonk, NY, USA) for the allocation of the students, who were stratified by center with a 1:1 allocation using a fixed block size of 6 (Rv. Uniform [0, 1]) in both parallel subgroups.

# 8b) Type of randomisation; details of any restriction (such as blocking and block size)

#### Does your paper address CONSORT subitem 8b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Computer-generated lists of random numbers were created using the Random Number Generator in IBM SPSS software (version 23; IBM, Armonk, NY, USA) for the allocation of the students, who were stratified by center with a 1:1 allocation using a fixed block size of 6 (Rv. Uniform [0, 1]) in both parallel subgroups.

9) Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned

#### Does your paper address CONSORT subitem 9? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The allocation sequence was concealed before implementation of the M-TEL module, and the module adhered to our computer-generated randomization protocol.

# 10) Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions

Does your paper address CONSORT subitem 10? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Computer-generated lists of random numbers were created using the Random Number Generator in IBM SPSS software (version 23; IBM, Armonk, NY, USA) for the allocation of the students, who were stratified by center with a 1:1 allocation using a fixed block size of 6 (Rv. Uniform [0, 1]) in both parallel subgroups. Sixty undergraduate medical students were screened, all of whom

(median age 23 years, range 22–26 years; 36 males [60%] and 24 females [40%]) were randomized 1:1 to the IM group or PPS group as

# 11a) If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how

NPT: Whether or not administering co-interventions were blinded to group assignment

#### 11a-i) Specify who was blinded, and who wasn't

Specify who was blinded, and who wasn't. Usually, in web-based trials it is not possible to blind the participants [1, 3] (this should be clearly acknowledged), but it may be possible to blind outcome assessors, those doing data analysis or those administering co-interventions (if any).

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential


#### Does your paper address subitem 11a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

After assignment, non of study participants was blinded.	

# 11a-ii) Discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator"

Informed consent procedures (4a-ii) can create biases and certain expectations - discuss e.g., whether participants knew which intervention was the "intervention of interest" and which one was the "comparator".



#### Does your paper address subitem 11a-ii?

Blinding to the purpose of the study during recruitment was maintained to minimize preparation bias.

# 11b) If relevant, description of the similarity of interventions

(this item is usually not relevant for ehealth trials as it refers to similarity of a placebo or sham intervention to a active medication/intervention)

#### Does your paper address CONSORT subitem 11b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

# 12a) Statistical methods used to compare groups for primary and secondary outcomes

NPT: When applicable, details of whether and how the clustering by care providers or centers was addressed

#### Does your paper address CONSORT subitem 12a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Because the primary outcome measure (percentage change in MCQ score) was not normally distributed according to the D'Agostino-Pearson omnibus normality test, percentage changes ([after value-before value]/[before value] × 100) in MCQ and MST, GSS, and AttrakDiff2 scores were compared between groups using the Wilcoxon signed rank test, Mann-Whitney U test, or Kruskal-Wallis test as appropriate. Categorical variables were analyzed using Fisher's exact test, and the Spearman correlation test was used to analyze the relationship between

#### 12a-i) Imputation techniques to deal with attrition / missing values

Imputation techniques to deal with attrition / missing values: Not all participants will use the intervention/comparator as intended and attrition is typically high in ehealth trials. Specify how participants who did not use the application or dropped out from the trial were treated in the statistical analysis (a complete case analysis is strongly discouraged, and simple imputation techniques such as LOCF may also be problematic [4]).

1 2 3 4 5 subitem not at all important O O O O O essential

#### Does your paper address subitem 12a-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No missing value in this study.

# 12b) Methods for additional analyses, such as subgroup analyses and adjusted analyses

#### Does your paper address CONSORT subitem 12b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

See above.

### X26) REB/IRB Approval and Ethical Considerations [recommended as subheading under "Methods"] (not a CONSORT item)

#### X26-i) Comment on ethics committee approval

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem X26-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This study was approved by the Institutional Review Board of Chang Gung Medical Foundation (No: 105-5290C), and all procedures were conducted in compliance with the Helsinki Declaration of 1975. The participants were informed about the aims of the study and written informed consent was obtained from all participants.

1 2 3 4 5

#### x26-ii) Outline informed consent procedures

Outline informed consent procedures e.g., if consent was obtained offline or online (how? Checkbox, etc.?), and what information was provided (see 4a-ii). See [6] for some items to be included in informed consent

1 2 3 4 5 subitem not at all important O O O O essentia	documents.						
subitem not at all important 🔘 🔘 💿 🔘 essentia		1	2	3	4	5	
	subitem not at all important	$\bigcirc$	$\bigcirc$	۲	$\bigcirc$	$\bigcirc$	essential

#### Does your paper address subitem X26-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No outline informed consent in this study.
//

#### X26-iii) Safety and security procedures

Safety and security procedures, incl. privacy considerations, and any steps taken to reduce the likelihood or detection of harm (e.g., education and training, availability of a hotline)

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	essential

#### Does your paper address subitem X26-iii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



### RESULTS

### 13a) For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome

NPT: The number of care providers or centers performing the intervention in each group and the number of patients treated by each care provider in each center

#### Does your paper address CONSORT subitem 13a? \*

Sixty undergraduate medical students were screened, all of whom (median age 23 years, range 22–26 years; 36 males [60%] and 24 females [40%]) were randomized 1:1 to the IM group or PPS group as shown in the Consolidated Standards of Reporting Trials flow diagram (Figure 3).

# 13b) For each group, losses and exclusions after randomisation, together with reasons

# Does your paper address CONSORT subitem 13b? (NOTE: Preferably, this is shown in a CONSORT flow diagram) \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Sixty undergraduate medical students were screened, all of whom (median age 23 years, range 22–26 years; 36 males [60%] and 24 females [40%]) were randomized 1:1 to the IM group or PPS group as shown in the Consolidated Standards of Reporting Trials flow diagram (Figure 3). Table 1 summarizes the variables of interest for the overall study cohort. There were no significant differences in age, sex, cognitive style, MCQ, or MST scores between the two groups at baseline.


#### 13b-i) Attrition diagram

Strongly recommended: An attrition diagram (e.g., proportion of participants still logging in or using the intervention/comparator in each group plotted over time, similar to a survival curve) or other figures or tables demonstrating usage/dose/engagement.

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	essential


#### Does your paper address subitem 13b-i?

Copy and paste relevant sections from the manuscript or cite the figure number if applicable (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study



### 14a) Dates defining the periods of recruitment and followup

#### Does your paper address CONSORT subitem 14a? \*



## 14b) Why the trial ended or was stopped (early)

#### Does your paper address CONSORT subitem 14b? \*


Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The trial stopped after recruitment of a sufficient sample size.

# 15) A table showing baseline demographic and clinical characteristics for each group

NPT: When applicable, a description of care providers (case volume, qualification, expertise, etc.) and centers (volume) in each group

#### Does your paper address CONSORT subitem 15? \*



participants, if known. 1 2 3 4 5 subitem not at all important O O O O essential

#### Does your paper address subitem 15-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Table 1 summarizes the variables of interest for the overall study cohort.
There were no significant differences in age, sex, cognitive style, MCQ, or
MST scores between the two groups at baseline.

# 16) For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups

#### 16-i) Report multiple "denominators" and provide definitions

Report multiple "denominators" and provide definitions: Report N's (and effect sizes) "across a range of study participation [and use] thresholds" [1], e.g., N exposed, N consented, N used more than x times, N used more than y weeks, N participants "used" the intervention/comparator at specific pre-defined time points of interest (in absolute and relative numbers per group). Always clearly define "use" of the intervention.



#### Does your paper address subitem 16-i? \*

Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1). The median percentage changes in MCQ and MST scores were 50% (interquartile range 17–80%, P<.001) and 13% (interquartile range 0–33%, P=.006), respectively. The M-TEL positively impacted the GSS, PQ, HQ-S, HQ-I, and ATT (all P<.001). The PPS group had significant improvements in knowledge (P<.001) and competence (P=.001), whereas the IM group had a significant improvement in

#### 16-ii) Primary analysis should be intent-to-treat

Primary analysis should be intent-to-treat, secondary analyses could include comparing only "users", with the appropriate caveats that this is no longer a randomized sample (see 18-i).



#### Does your paper address subitem 16-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

All of the participants (100%) received the intended intervention after randomization, and there was no deviation from the study protocol.

### 17a) For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)

#### Does your paper address CONSORT subitem 17a? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Data are expressed as media	an (interquartile range).
	//

#### 17a-i) Presentation of process outcomes such as metrics of use and intensity of use

In addition to primary/secondary (clinical) outcomes, the presentation of process outcomes such as metrics of use and intensity of use (dose, exposure) and their operational definitions is critical. This does not only refer to metrics of attrition (13-b) (often a binary variable), but also to more continuous exposure metrics such as "average session length". These must be accompanied by a technical description how a metric like a "session" is defined (e.g., timeout after idle time) [1] (report under item 6a).

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 17a-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Overall, all of the participants showed significant improvements in MCQ score (P<.001) and MST score (P=.006) after 100 minutes of e-learning (Table 1).

# 17b) For binary outcomes, presentation of both absolute and relative effect sizes is recommended

#### Does your paper address CONSORT subitem 17b? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Yes.

# 18) Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory

#### Does your paper address CONSORT subitem 18? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

We further compared the effect of modified cognitive style and M-TEL module on outcomes using Friedman's test (Table 4). Both modified cognitive style and M-TEL module had significant effects on percentage changes in MCQ score and GSS, but no significant effect on percentage changes in PQ and HQ-S. The M-TEL module had significant effects on MST score, HQ-I, and ATT, whereas modified cognitive style did not have any significant effects.

#### 18-i) Subgroup analysis of comparing only users

A subgroup analysis of comparing only users is not uncommon in ehealth trials, but if done, it must be stressed that this is a self-selected sample and no longer an unbiased sample from a randomized trial (see 16-iii).

	1	2	3	4	5	
subitem not at all important	$\bigcirc$	$\bigcirc$	$\bigcirc$	$\bigcirc$	۲	essential

#### Does your paper address subitem 18-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

In this study, most of the participants were categorized as classical FI learners and we were unable to determine which FI learners were more suitable for M-TEL using classical classification [29]. El-Banna proposed that a field-intermediate (FINT) category exists between FD and FI categories [34]. Accordingly, we adopted this modified classification of cognitive style (FD: <mean GEFT score - standard deviation [SD] × 0.25; FINT: ≥mean GEFT score - SD × 0.25 & ≤mean GEFT score + SD × 0.25; FI: >mean GEFT score + SD × 0.25); thereby resulting in three

# 19) All important harms or unintended effects in each group

(for specific guidance see CONSORT for harms)

#### Does your paper address CONSORT subitem 19? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no important harms nor unintended effects in each group.			
	1		

#### 19-i) Include privacy breaches, technical problems

Include privacy breaches, technical problems. This does not only include physical "harm" to participants, but also incidents such as perceived or real privacy breaches [1], technical problems, and other unexpected/unintended incidents. "Unintended effects" also includes unintended positive effects [2].

1 2 3 4 5 subitem not at all important O O O O essential

#### Does your paper address subitem 19-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There were no privacy nor technical problems in each group.

#### 19-ii) Include qualitative feedback from participants or observations from staff/researchers

Include qualitative feedback from participants or observations from staff/researchers, if available, on strengths and shortcomings of the application, especially if they point to unintended/unexpected effects or uses. This includes (if available) reasons for why people did or did not use the application as intended by the developers.

1 2 3 4 5

subitem not at all important  $\bigcirc$   $\bigcirc$   $\bigcirc$   $\bigcirc$  essential

#### Does your paper address subitem 19-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

No, we did not include qualitative feedback and observations in this study.
<i>I</i>

### DISCUSSION

# 22) Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence

NPT: In addition, take into account the choice of the comparator, lack of or partial blinding, and unequal expertise of care providers or centers in each group

# 22-i) Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use)

Restate study questions and summarize the answers suggested by the data, starting with primary outcomes and process outcomes (use).



#### Does your paper address subitem 22-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The main findings of this study are that M-TEL outside the classroom can help undergraduate medical students to strengthen their knowledge and competence of emergent ORL-HNS disorders, and to provide an enjoyable learning experience overall. In addition, our findings suggest that millennials can significantly gain knowledge rather than reinforce competence using an IM module. Despite the similar efficacy of both modules, the students preferred the IM module to the PPS module due to it being more efficient and enjoyable to use. Although the classical

**22-ii) Highlight unanswered new questions, suggest future research** Highlight unanswered new questions, suggest future research.

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 22-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Using this modified classification, we found that all of the participants significantly gained knowledge and competence after the M-TEL course regardless of cognitive style. In this short-term M-TEL course, the FINT learners had the significantly highest knowledge gain and satisfaction regardless of which M-TEL module they used compared to the modified FD and FI learners, who needed a more specific design of instructional material. For example, the FD learners needed an easy to use and follow style of M-TEL, whereas the FI learners wanted a more vigorous

# 20) Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses

#### 20-i) Typical limitations in ehealth trials

Typical limitations in ehealth trials: Participants in ehealth trials are rarely blinded. Ehealth trials often look at a multiplicity of outcomes, increasing risk for a Type I error. Discuss biases due to non-use of the intervention/usability issues, biases through informed consent procedures, unexpected events.

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 💿 essential

#### Does your paper address subitem 20-i? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

There are several limitations to this randomized controlled trial. First, this study was quasi-experimental due to the lack of probability sampling. Even though we selected individuals based on their availability to the investigators, the sample size was representative of the target population (>50% were classmates). Second, used different posttest questions to measure learning outcomes, and the interaction between taking a pretest and the intervention itself may threaten the external validity. A design which does not use a pretest would have

# 21) Generalisability (external validity, applicability) of the trial findings

NPT: External validity of the trial findings according to the intervention, comparators, patients, and care providers or centers involved in the trial

#### 21-i) Generalizability to other populations

Generalizability to other populations: In particular, discuss generalizability to a general Internet population, outside of a RCT setting, and general patient population, including applicability of the study results for other organizations

1 2 3 4 5

subitem not at all important 🔘 🔘 🔘 🔘 essential

#### Does your paper address subitem 21-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information

not in the ms, or briefly explain why the item is not applicable/relevant for your study

Our results demonstrate that M-TEL for medical education can facilitate the learning of complex topics with promising results in terms of gains in knowledge, competence and attitude compared to other forms of e-learning [42-44]. However, the learners using the gamified IM model still struggled with performance in MSTs. Therefore, M-TEL may not be an approach that is suitable for all. For example, M-TEL cannot completely replace traditional face-to-face lectures, since most students indicate that they consider traditional teaching as the basis of their education [45].

# 21-ii) Discuss if there were elements in the RCT that would be different in a routine application setting

Discuss if there were elements in the RCT that would be different in a routine application setting (e.g., prompts/reminders, more human involvement, training sessions or other co-interventions) and what impact the omission of these elements could have on use, adoption, or outcomes if the intervention is applied outside of a RCT setting.



#### Does your paper address subitem 21-ii?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Among millennial medical students, better academic achievement is associated with effort management, organized studying, deep learning, and the optimized use of social networking [1,2,11]. Since learners can start and stop M-TEL at any time or place of their choosing [52], this learning modality may be superior to traditional classroom lectures with regards to self-directed effort management and organized study, and allow them to achieve deep understanding by repeatedly reviewing the instructional materials. The best way to control the time spent using

### OTHER INFORMATION

### 23) Registration number and name of trial registry

#### Does your paper address CONSORT subitem 23? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Registration: ClinicalTrials.gov NCT02971735, (http://clinicaltrials.gov/show/NCT02971735)

# 24) Where the full trial protocol can be accessed, if available

Does your paper address CONSORT subitem 24? \*

Cite a Multimedia Appendix, other reference, or copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

Registration: ClinicalTrials.gov NCT02971735, (http://clinicaltrials.gov/show/NCT02971735)

# 25) Sources of funding and other support (such as supply of drugs), role of funders

#### Does your paper address CONSORT subitem 25? \*

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

This work was financially supported by grants from the Ministry of Science and Technology, Taiwan, R.O.C. (104-2511-S-182-010 & 105-2511-S-182A-006) and a grant from the Chang Gung Medical Foundation, Taiwan, R.O.C. (CMRPG3F1091).

## X27) Conflicts of Interest (not a CONSORT item)

#### X27-i) State the relation of the study team towards the system being evaluated

In addition to the usual declaration of interests (financial or otherwise), also state the relation of the study team towards the system being evaluated, i.e., state if the authors/evaluators are distinct from or identical with the developers/sponsors of the intervention.



#### Does your paper address subitem X27-i?

Copy and paste relevant sections from the manuscript (include quotes in quotation marks "like this" to indicate direct quotes from your manuscript), or elaborate on this item by providing additional information not in the ms, or briefly explain why the item is not applicable/relevant for your study

The authors declare no competing financial interests.

## About the CONSORT EHEALTH checklist

As a result of using this checklist, did you make changes in your manuscript? \*

https://docs.google.com/forms/d/e/1FAIpQLSfZBSUp1bwOc\_OimqcS64RdfIAFvmrTSkZQL2-3O8O9hrL5Sw/viewform?hl=en\_US&formkey=dGI... 33/35

- yes, major changes
- yes, minor changes
- 🔵 no

What were the most important changes you made as a result of using this checklist?

How much time did you spend on going through the checklist INCLUDING making changes in your manuscript \*

About 4 hours

As a result of using this checklist, do you think your manuscript has improved? \*

- yes
- 🔘 no
- Other:

#### Would you like to become involved in the CONSORT EHEALTH group?

This would involve for example becoming involved in participating in a workshop and writing an "Explanation and Elaboration" document

- yes
- no
- Other:

#### Any other comments or questions on CONSORT EHEALTH

## STOP - Save this form as PDF before you click submit

To generate a record that you filled in this form, we recommend to generate a PDF of this page (on a Mac, simply select "print" and then select "print as PDF") before you submit it.

When you submit your (revised) paper to JMIR, please upload the PDF as supplementary file.

Don't worry if some text in the textboxes is cut off, as we still have the complete information in our database. Thank you!

### Final step: Click submit !

Click submit so we have your answers in our database!

Submit

Never submit passwords through Google Forms.

Powered by

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Additional Terms